Lbp Am Sa Has $21.27 Million Stake in Cencora, Inc. (NYSE:COR)

LBP AM SA reduced its stake in Cencora, Inc. (NYSE:COR - Free Report) by 3.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,495 shares of the company's stock after selling 2,855 shares during the quarter. LBP AM SA's holdings in Cencora were worth $21,272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after purchasing an additional 48 shares during the period. Hoey Investments Inc. bought a new position in Cencora during the 1st quarter valued at about $28,000. Banque Transatlantique SA purchased a new stake in Cencora in the fourth quarter worth approximately $29,000. SBI Securities Co. Ltd. purchased a new stake in Cencora during the fourth quarter valued at $30,000. Finally, Vermillion Wealth Management Inc. bought a new stake in shares of Cencora during the 4th quarter valued at about $38,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Down 0.8%

NYSE COR traded down $2.25 during trading on Friday, reaching $295.07. 970,795 shares of the company's stock were exchanged, compared to its average volume of 1,507,719. The company has a 50 day moving average price of $291.85 and a two-hundred day moving average price of $269.23. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The stock has a market cap of $57.19 billion, a P/E ratio of 34.23, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the company earned $3.80 earnings per share. The company's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's payout ratio is currently 25.52%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. UBS Group upped their price objective on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Robert W. Baird upped their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Citigroup boosted their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average price target of $306.33.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at $13,766,900.06. This represents a 9.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock worth $9,812,296 over the last three months. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.